In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ziarco Pharma Ltd.

www.ziarcopharma.com

Latest From Ziarco Pharma Ltd.

Start-Up Quarterly Statistics, Q4 2016

A review of biopharma start-up dealmaking and financing from October through December 2016, based on data from Strategic Transactions.

StartUps and SMEs Financing

Novartis’s Evolving R&D: An Interview With CMO Narasimhan At J.P. Morgan

Novartis is under pressure to deliver new drugs in areas like oncology, cardiovascular disease and dermatology, where it is making significant investments. Chief Medical Officer Vasant Narasimhan talked about the company’s strategy in these areas and others, the company’s recent R&D reorganization and business development in an interview during the J.P. Morgan Healthcare Conference.

Commercial Companies

Deals Shaping the Medical Industry, January 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2016.

Deals BioPharmaceutical

Deal Watch: Bristol And Otsuka Pursue Oncolytic Virus Therapies Via Licensing Deals

Busy stretch before Christmas holidays sees two deals around oncolytic virus therapeutics, a Middle East partnership for Orexigen’s Contrave, immuno-oncology deals involving Pfizer and ElsaLys, and Roche and ImmuNext partnering to develop drugs targeting the VISTA pathway.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
  • Therapeutic Areas
  • Dermatology
  • Immune Disorders
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Ziarco Pharma Ltd.
  • Senior Management
  • Lynn Purkins, PhD, Chief Dev. Officer
    Wai (Steve) Liu, PhD, CSO
    Pablo Jimenez, MD, CMO
    Arvind Hundal, CBO
  • Contact Info
  • Ziarco Pharma Ltd.
    Phone: 01304 806889
    Innovation House/Discovery Pk/Office 49
    Ramsgate Rd.
    Sandwich , CT13 9ND
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register